Mankind Pharma
Book Building issueMainboard₹4,326 Cr issue
+20.37%
Listing gain over issue price
Issue size
₹4,326 Cr
1 lot at cut-off
₹14,040
Lot size
13shares
Open
25 Apr 2023
Close
27 Apr 2023
Allotment
03 May 2023
Listing
09 May 2023
Listing performance
Issue price
₹1,080
Listed at
₹1,300
Listing-day close
₹1,424.05
Latest price
₹2,212.60
Close on 23 Oct 2026
Listing gain
+20.37%
Return since issue
+104.87%
Scheduled dates
Tentative timetable — a past date is not confirmation the step completed
Issue details
- IPO date
- 25 Apr 2023 – 27 Apr 2023
- Listing date
- 09 May 2023
- Face value
- ₹1 per share
- Issue price
- ₹1,080 per share
- Lot size
- 13 shares
- Issue type
- Book Building issue
- Total issue size
- ₹4,326 Cr
- Market cap at offer price
- ₹43,264 Cr
- Promoter holding
- 79.00% → 76.50% pre-issue → post-issue
- ISIN
- INE634S01028
- Registrar
- Kfin Technologies Ltd.
- Lead managers
- Kotak Mahindra Capital Co.Ltd.
- Registered office
- 208, Okhla Industrial Estate, Phase-III, New Delhi
Reservation and application size
How the issue is split between investor categories, and what each may bid
| Investor category | Shares | % of net | % of total |
|---|---|---|---|
| Anchor investor · within QIB | 1,20,17,652 | — | — |
Application size
Minimum 13 shares per lot, in multiples, at ₹1,080
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 13 | ₹14,040 |
| Retail (max) | 14 | 182 | ₹1,96,560 |
| S-HNI (min) | 15 | 195 | ₹2,10,600 |
| S-HNI (max) | 71 | 923 | ₹9,96,840 |
| B-HNI (min) | 72 | 936 | ₹10,10,880 |
Category limits
| Category | Bid size | Cut-off |
|---|---|---|
| Retail (RII) | Up to ₹2 lakh | Yes |
| Small HNI (sNII) | ₹2 lakh – ₹10 lakh | No |
| Big HNI (bNII) | Above ₹10 lakh | No |
| Employee | Up to ₹5 lakh | Yes |
Bidding at cut-off means accepting the final issue price without naming one. Only retail and employee applicants may do so.
Anchor investors
Institutional allocation placed a day before the issue opens, carved out of the QIB portion and locked in after listing.
Shares allocated
1,20,17,652
Anchor portion
₹1,298 Cr
at ₹1,080 per share
Valuation and performance
Valuation at offer price
₹1,080 per share
| Metric | Pre-issue | Post-issue |
|---|---|---|
| EPS (₹) | 33.20 | — |
| P/E (×) | 32.53 | — |
| Market cap | — | ₹43,264 Cr |
Key performance indicators
Latest reported period
- Return on net worth
- 27.70%
- ROCE
- 26.10%
- PAT margin
- 18.67%
- NAV per share
- ₹153.65
Single period as reported. Year-on-year movement is in the financials table below, where every period is published.
About Mankind Pharma
Mankind Pharma Limited, incorporated on July 3, 1991, is a pharmaceutical company focused on the Indian domestic market where it develops, manufactures and markets a diverse range of pharmaceutical formulations and consumer healthcare products. The company is present across acute and chronic therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients and respiratory. In consumer healthcare, it has established brands in condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations. As of December 31, 2022, the company operates 25 manufacturing facilities across India and has a dedicated R&D center with four units. The company derives 96.79% of its revenue from India, with major overseas markets in the United States, Bangladesh, Sri Lanka and Nepal.
Company Analysis
from RHPMankind Pharma is India's fourth-largest pharmaceutical company by domestic sales, developing, manufacturing and marketing diverse pharmaceutical formulations and consumer healthcare products primarily for the Indian market.
Mankind Pharma Limited, incorporated on July 3, 1991, is a pharmaceutical company focused on the Indian domestic market where it develops, manufactures and markets a diverse range of pharmaceutical formulations and consumer healthcare products. The company is present across acute and chronic therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients and respiratory. In consumer healthcare, it has established brands in condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations. As of December 31, 2022, the company operates 25 manufacturing facilities across India and has a dedicated R&D center with four units. The company derives 96.79% of its revenue from India, with major overseas markets in the United States, Bangladesh, Sri Lanka and Nepal.
pharmaceuticalsconsumer healthcare
Objects of the Issue
- Offer for Sale by the Selling Shareholders and achieve benefits of listing ₹43,263.55 million p.32
- Offer for Sale of Equity Shares by Selling Shareholders ₹43,263.55 million p.99
- Achieve benefits of listing on Stock Exchanges p.141
- Not specified in Part 7
- Not found in this document section
Issue Structure
- Total Issue
- ₹43,263.55 million
- Fresh Issue
- Not applicable
- Offer for Sale
- 40,058,844 Equity Shares aggregating to ₹43,263.55 million
- Price Band
- ₹1,026 to ₹1,080 per Equity Share
- Lot Size
- 13 Equity Shares and in multiples of 13 Equity Shares thereafter (Bid Lot)
- Face Value
- ₹1 per Equity Share
Business Model
The company earns revenue through the manufacture and sale of pharmaceutical formulations and consumer healthcare products, primarily through distribution to retailers, wholesalers and dispensing doctors in India. It manufactures approximately 74.45% of its products in-house, while approximately 25.55% of its revenue comes from products manufactured through third-party manufacturing arrangements as of nine months ended December 31, 2022.
Business Segments
Develops, manufactures and markets pharmaceutical formulations across acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients and respiratory
Manufactures and markets consumer healthcare products in condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations
Products in the anti-infectives therapeutic area including antibiotics and related medicines
Products in the cardiovascular therapeutic area
Products in the gastrointestinal therapeutic area
Sale of prescription pharmaceutical formulations and over-the-counter medications across multiple therapeutic areas in India
Portfolio includes therapeutic classes such as penicillin, cephalosporin, macrolides and quinolones used to treat respiratory tract infections, urinary tract infections and skin infections
Portfolio includes angiotensin receptor blockers and calcium channel blockers for treatment of hypertension
Portfolio includes therapeutic molecules such as mecobal, ondansetron, rabeprazole, pantoprazole and ofloxacin for treatment of gastrointestinal conditions
Portfolio includes multi-vitamins and nutrients such as vitamin B-12, mecobalamin and arginine combinations
Portfolio includes cough suppressants, cough expectorants and antihistamines
Portfolio includes oral anti-diabetic medication in type 2 diabetes care management
Focus on emergency contraceptives and treatment of female infertility
Portfolio includes antifungal and acne medicines used in treatment of skin conditions
Manforce brand condoms positioned as socially responsible brand seeking to improve sexual wellness. Offers wide variety of sexual wellness products including lubricants and pre-mature ejaculation gels.
Prega News is an easy-to-use home pregnancy detection kit that detects pregnancy using urine samples. Positioned as socially aware brand with positive ethos.
Unwanted-72 emergency contraceptive brand launched in 2007
Manufactures and sells emergency contraceptive tablets (Unwanted-72) and birth control pills (Unwanted-21 Days)
Manufactures Gas-O-Fast, an ayurvedic multi-flavor oral antacid powder used to relieve symptoms of acidity, heartburn and indigestion, available in powder and effervescent sugar-free tablet forms
Manufactures Health OK, a multi-vitamin tablet that helps improve energy levels and boosts overall health and immunity, also offered as multi-vitamin gummies for children
Manufactures AcneStar, an anti-inflammatory and anti-bacterial gel containing clindamycin and nicotinamide used for treatment of acne
Sells pharmaceutical products in 21 countries across regulated and semi-regulated emerging markets in the United States, Latin America, Southeast Asia, Africa, the Middle East and the Commonwealth of Independent States through subsidiaries and distribution arrangements
Manufacturing and trading of pharmaceutical formulations
Manufacturing and trading of consumer healthcare products
Diagnostic services through subsidiaries
Manufacture and sale of pharmaceutical products and consumer healthcare products across multiple therapeutic categories
Development and management of real estate properties and hospitality investments
Manufacture and sale of pharmaceutical formulations and healthcare products
Sale of professional services
Sale of inventories related to housing project development
Manufacturing and sale of pharmaceutical products and healthcare products
Manufacturing and marketing of pharmaceutical formulations across acute and chronic therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients and respiratory
Manufacturing and marketing of consumer healthcare products in condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories
Sale of pharmaceutical products to overseas markets
SWOT Analysis
Strengths
- • Fourth largest pharma company by domestic sales, third by volume(p.29)
- • Diversified product portfolio across multiple therapeutic areas(p.29)
- • Strong established brands in consumer healthcare(p.29)
- • Significant manufacturing capacity with 25 facilities(p.49)
- • Fourth largest pharma company in India by domestic sales(p.155)
- • Fastest organic growth among top 5 pharma companies(p.155)
- • Third highest growth rate among top 10 pharma companies(p.155)
- • Most prescribed pharmaceutical company with 15.4% prescription share(p.155)
- • Strong pan-India distribution with 11,691 medical representatives(p.155)
- • Market leadership in consumer healthcare categories(p.155)
- • Market-leading position in select consumer healthcare segments(p.215)
- • Vertically integrated API manufacturing capabilities(p.216)
- • Extensive manufacturing infrastructure with regulatory approvals(p.216)
- • Strong R&D capabilities with experienced scientific team(p.228)
- • Global regulatory certifications enabling multi-market operations(p.216)
- • Established international presence across 21 countries(p.215)
- • Large diversified sales and distribution network(p.229)
- • Significant intellectual property portfolio(p.230)
- • Established family-led management with long tenure and deep industry experience(p.286)
- • Diversified senior management team with pharmaceutical expertise across multiple functions(p.286)
- • Strong financial performance with robust profit generation(p.310)
- • Established accounting policies and revenue recognition practices demonstrating operational maturity(p.322)
- • Diversified investment portfolio with multiple mutual fund holdings across asset classes(p.347)
- • Substantial capital work-in-progress indicating ongoing business expansion and modernization(p.337)
- • Significant intangible asset base from pharmaceutical brand acquisitions(p.340)
- • Strong market position with established manufacturing and distribution network(p.354)
- • Significant cash reserves and liquidity position(p.352)
- • Diversified shareholder base with promoter ownership of 67.29%(p.354)
- • Profitable operations with consistent growth in retained earnings(p.355)
- • Substantial investment in manufacturing infrastructure and subsidiaries across pharmaceutical value chain(p.427)
- • Diversified portfolio of related pharmaceutical entities including bulk drug manufacturers and packaging companies(p.427)
- • International presence through subsidiaries in multiple countries including USA, Singapore, UAE, and Nepal(p.427)
- • Strong profitability with restated basic earnings per share of INR 24.87 for nine months ended December 31, 2022(p.424)
- • Fourth largest domestic pharmaceutical company by sales volume(p.454)
- • Strong brand portfolio with 36 brands exceeding ₹500 million in domestic sales(p.455)
- • Highest prescription share in Indian pharmaceutical market(p.455)
- • Leader in consumer healthcare categories(p.455)
- • Largest medical representative field force(p.455)
- • Organic growth trajectory with youngest company status among top 5(p.455)
- • Strong presence in high-growth Tier-II to Tier-IV cities(p.455)
- • Fastest market share growth among top 10 companies(p.455)
Weaknesses
- • Heavy concentration of manufacturing in Himachal Pradesh(p.49)
- • Significant dependence on third-party suppliers and manufacturers(p.37)
- • High attrition rate in field force(p.54)
- • Limited control over third-party manufacturer quality(p.52)
- • Significant related party transactions(p.38)
- • High attrition among medical representatives and field managers(p.54)
- • Dependence on non-exclusive distributor relationships(p.54)
- • Revenue concentration in specific therapeutic areas(p.55)
- • High debt obligations and covenant restrictions(p.56)
- • Significant related-party transactions(p.57)
- • Untraced and discrepant corporate records(p.67)
- • Leasehold dependency for key facilities(p.68)
- • Former employee complaints post-acquisition(p.61)
- • Certain corporate records not traceable or have discrepancies(p.63)
- • Dependence on Ind AS accounting which may differ from international standards(p.95)
- • Significant dependence on third-party manufacturers(p.230)
- • Concentrated raw material supplier base(p.230)
- • Underutilized manufacturing capacity across facilities(p.220)
- • Significant reliance on limited customer base(p.229)
- • High concentration of promoter shareholding and family control(p.290)
- • Complex family trust structures with potential succession and governance risks(p.291)
- • Related party transactions with group companies creating potential conflicts(p.276)
- • Reliance on key managerial personnel concentrated in family members(p.290)
- • Substantial outstanding statutory dues across multiple entities and years(p.331)
- • Multiple tax disputes pending across entities with significant demand amounts(p.332)
- • Substantial goodwill and intangible asset impairment charges indicating fair value pressure(p.340)
- • Investment impairment provisions indicating valuation stress in associate companies(p.345)
- • High levels of capital work-in-progress over multiple years indicating project delays(p.337)
- • Significant increase in current working capital demand loans indicating liquidity pressure(p.358)
- • High provision for expected sales returns indicating product quality or demand issues(p.365)
- • Material contingent liabilities and unresolved tax disputes(p.375)
- • Concentration of trade receivables in government and large customer base(p.352)
- • Significant goodwill impairment recorded in recent period(p.373)
- • Significant dependence on related party transactions with multiple subsidiaries and associates for sourcing and distribution(p.409)
- • Heavy concentration of manufacturing operations within the consolidated group structure requiring complex inter-company eliminations(p.437)
- • Underperforming foreign subsidiary Lifestar Pharma LLC showing substantial losses(p.437)
- • High proportion of non-controlling interests (INR 1,796.75 millions) indicating limited full ownership control across subsidiaries(p.436)
- • Negative capital reserves totaling INR 9,089.82 millions from acquisitions and demerger operations(p.426)
- • Heavy dependence on domestic market with limited international presence(p.454)
- • High depreciation expenses from recent acquisitions reducing profitability(p.476)
- • Rising employee benefits expenses reducing margins(p.473)
- • Significant increase in inventories requiring working capital(p.476)
- • Exposure to commodity price fluctuations affecting raw material costs(p.461)
- • Regulatory compliance challenges with multiple drug pricing and pricing disclosure violations(p.488)
- • Multiple product quality issues and regulatory actions against company products(p.489)
- • Significant litigation and unfair labour practice allegations against promoters and company(p.489)
- • Transfer pricing adjustment orders and ongoing tax proceedings(p.490)
- • Promoter involvement in regulatory and criminal proceedings(p.487)
- • Substantial outstanding dues to creditors(p.496)
Opportunities
- • Growing Indian pharmaceutical market with strong forecast growth(p.29)
- • Growing consumer healthcare market with favorable demographics(p.29)
- • Expansion into emerging markets beyond India(p.37)
- • Expansion in metro and Class I cities(p.59)
- • Growth in consumer healthcare business(p.59)
- • Digital platform development for doctor engagement(p.59)
- • Alternative distribution channels expansion(p.59)
- • New product development in niche molecules(p.72)
- • New chemical entity development for chronic diseases(p.73)
- • Chronic therapeutic areas growing 1.4x faster than market(p.155)
- • Expanding covered market presence(p.155)
- • Third highest number of billion-rupee brands in IPM(p.155)
- • Enhanced visibility and brand from listing(p.141)
- • Expansion in emerging therapeutic segments(p.228)
- • Development of novel drug delivery systems(p.228)
- • Geographic expansion in international markets(p.215)
- • Strategic acquisitions to strengthen product portfolio(p.250)
- • Digital engagement platforms for healthcare stakeholders(p.229)
- • Platform for strategic acquisitions and group consolidation(p.295)
- • Diversification through group companies in diagnostics and nutraceuticals(p.297)
- • International expansion through overseas subsidiaries(p.308)
- • Expansion of pharmaceutical product portfolio through acquisition of established brands(p.340)
- • Growing pharmaceutical and consumer healthcare market with diverse product range(p.322)
- • Real estate and hospitality development through joint venture partnerships(p.345)
- • Government incentive schemes for capital investment and export promotion(p.337)
- • Government support through export incentives and duty benefits(p.371)
- • Geographic expansion with growing international revenue contribution(p.371)
- • Expansion into new business segments including real estate(p.371)
- • Capital investment in manufacturing capacity through subsidiary companies(p.375)
- • Expansion of international markets particularly through trading subsidiaries in USA, Singapore, UAE and Nepal(p.427)
- • Growth potential in pharmaceutical bulk drug manufacturing through wholly-owned Shree Jee Laboratory(p.413)
- • Vertical integration opportunities through manufacturing subsidiaries for condoms and pharmaceutical packaging materials(p.427)
- • Revenue growth trajectory with nine-month revenue of INR 66,967.66 millions versus INR 60,557.94 millions in prior year period(p.423)
- • Expansion in chronic therapeutic areas with higher growth potential(p.455)
- • Growing prevalence of chronic diseases offering lifetime patient value(p.458)
- • Strategic acquisitions of brands and in-licensing opportunities(p.458)
- • Planned expansion into new therapeutic areas including anti-diabetic and cardiovascular(p.458)
- • Presence in high-growth non-metros with faster market expansion rate(p.455)
- • Leverage of existing brand infrastructure for new molecule launches(p.457)
Threats
- • Regulatory risks and manufacturing approval delays(p.50)
- • Potential stricter pharmaceutical marketing regulations(p.37)
- • Market concentration risk in specific therapeutic areas(p.37)
- • Operational disruptions from natural disasters and pandemics(p.49)
- • Supply chain vulnerability and commodity price volatility(p.52)
- • Heavy dependence on domestic Indian market(p.53)
- • Increased competition in key markets(p.37)
- • Marketing practice regulations by pharmaceutical companies(p.54)
- • Intense industry competition(p.64)
- • Pricing pressure from competitors and price controls(p.71)
- • Government price controls and regulations(p.63)
- • Product recall and quality control risks(p.62)
- • Regulatory inspection deficiencies(p.62)
- • Patent litigation and IP infringement risks(p.61)
- • Counterfeit drug market threats(p.73)
- • COVID-19 pandemic and supply chain disruptions(p.76)
- • Seasonal demand fluctuations(p.78)
- • Natural disasters and operational hazards(p.78)
- • Foreign exchange rate fluctuations(p.90)
- • Indian economic and political risks(p.91)
- • Compulsory licensing threat to patents(p.94)
- • India's sovereign debt rating risk(p.94)
- • Foreign investor restrictions limiting capital raising(p.95)
- • Constraints on foreign currency borrowing(p.96)
- • Difficulty enforcing foreign judgments against the company(p.96)
- • Share price volatility and no guarantee of active trading market(p.97)
- • Tax exposure on capital gains for investors(p.98)
- • Intense competition in pharmaceutical industry(p.230)
- • Price regulation and government control of pharmaceuticals(p.241)
- • Regulatory compliance burden and changing regulations(p.240)
- • Environmental and health-safety compliance requirements(p.244)
- • Supply chain disruptions and input cost volatility(p.230)
- • Unwilling promoter group member creating disclosure and governance uncertainty(p.295)
- • Regulatory scrutiny on related party transactions and affiliate dealings(p.276)
- • Board composition and independence challenges with dominance of family directors(p.278)
- • Significant tax litigation exposure with multiple assessment authorities(p.332)
- • Regulatory risks from GST and tax compliance requirements across jurisdictions(p.332)
- • Exposure to inventory obsolescence and markdown risks in pharmaceutical sector(p.351)
- • Foreign currency translation risks from international operations(p.325)
- • Lease obligation commitments with long-term payment obligations(p.343)
- • Regulatory and tax compliance risks including GST input credit disputes(p.375)
- • Significant exposure to income tax disputes and potential reassessment(p.375)
- • Product liability litigation and patent infringement risks(p.375)
- • Covenant compliance challenges noted in subsidiary operations(p.357)
- • Rising operational and employee benefit costs(p.372)
- • Substantial goodwill balance of INR 200.23 millions subject to impairment risk, with recent INR 38.52 millions impairment on JPR Labs(p.426)
- • Ongoing litigation and restructuring with Lifestar Pharma and Magnet Labs merger pending NCLT approval as of reporting date(p.427)
- • Significant financial obligations to related parties with borrowings from Pavi Buildwell of INR 444.77 millions(p.409)
- • Exposure to working capital volatility through substantial inter-company receivables and payables(p.413)
- • Intense competitive pressure in pharmaceutical market(p.484)
- • Regulatory risks from changing government policies and compliance requirements(p.462)
- • Commodity price volatility affecting raw material procurement(p.461)
- • Slowdown in pharmaceutical market growth affecting sales momentum(p.472)
- • Seasonal variations affecting sales patterns(p.484)
- • Loss of tax incentives affecting profitability(p.462)
- • Regulatory enforcement actions and pricing control regime compliance risks(p.487)
- • Intellectual property infringement litigation and design rights challenges(p.491)
- • Patent infringement litigation by competitors(p.491)
- • Trademark infringement suits against subsidiary entities(p.491)
- • Regulatory restrictions on advertising of drug categories(p.492)
- • Labour court disputes and industrial relations risks(p.489)
Promoters
| Name | Role | Pre-Issue | Post-Issue |
|---|---|---|---|
| Ramesh Juneja | Promoter | 2.64% | 2.31% |
| Rajeev Juneja | Promoter | 2.50% | 2.18% |
| Sheetal Arora | Promoter | 5.97% | 5.23% |
| Ramesh Juneja Family Trust | Promoter | 20.81% | 18.18% |
| Rajeev Juneja Family Trust | Promoter | 19.95% | 17.45% |
| Prem Sheetal Family Trust | Promoter | 15.42% | 13.49% |
| Cairnhill CIPEF Limited | Promoter Group/Investor Selling Shareholder | 6.08% | 5.32% |
| Cairnhill CGPE Limited | Investor Selling Shareholder | 0.92% | 0.81% |
| Beige Limited | Investor Selling Shareholder | 9.95% | 8.71% |
| Link Investment Trust | Investor Selling Shareholder | 0.05% | 0.04% |
| Ramesh Juneja | Promoter | — | — |
| Rajeev Juneja | Promoter/Managing Director | — | — |
| Sheetal Arora | Promoter | — | — |
| Ramesh Juneja | Promoter | 2.64% | 1.71% |
| Rajeev Juneja | Promoter | 2.50% | 1.62% |
| Sheetal Arora | Promoter | 5.97% | 5.27% |
| Ramesh Juneja Family Trust | Promoter | 20.81% | 20.81% |
| Rajeev Juneja Family Trust | Promoter | 19.95% | 19.95% |
| Prem Sheetal Family Trust | Promoter | 15.42% | 15.42% |
| Cairnhill CIPEF Limited | Public/Investor Selling Shareholder | 6.08% | — |
| Beige Limited | Public/Investor Selling Shareholder | 9.95% | — |
| Ramesh Juneja | Promoter | — | — |
| Rajeev Juneja | Promoter | — | — |
| Ramesh Juneja | Founder and Promoter | — | — |
| Rajeev Juneja | Promoter | — | — |
| Sheetal Arora | Promoter | — | — |
| Ramesh Juneja | Promoter | 2.64% | — |
| Rajeev Juneja | Promoter | 2.50% | — |
| Sheetal Arora | Promoter | 5.97% | — |
| Ramesh Juneja Family Trust | Promoter | — | — |
| Rajeev Juneja Family Trust | Promoter | — | — |
| Prem Sheetal Family Trust | Promoter | — | — |
| Data not available in this excerpt | Promoter | — | — |
| Ramesh Juneja | Promoter | 2.64% | — |
| Ramesh Juneja Family Trust (held in the name of Mr. Ramesh Juneja, Managing Trustee) | Promoter | 20.81% | — |
| Rajeev Juneja | Promoter | 2.50% | — |
| Rajeev Juneja Family Trust (held in the name of Mr. Rajeev Juneja, Managing Trustee) | Promoter | 19.95% | — |
| Sheetal Arora | Promoter | 5.97% | — |
| Prem Sheetal Family Trust (held in the name of Arora Family Private Limited, Trustee) | Promoter | 15.42% | — |
| — | Promoter | — | — |
| Ramesh Juneja | Promoter/Selling Shareholder | — | — |
| Rajeev Juneja | Promoter/Selling Shareholder | — | — |
| Sheetal Arora | Promoter/Selling Shareholder | — | — |
| Cairnhill CIPEF Limited | Selling Shareholder | — | — |
| Cairnhill CGPE Limited | Selling Shareholder | — | — |
| Beige Limited | Selling Shareholder | — | — |
| Link Investment Trust | Selling Shareholder | — | — |
Leadership
Ramesh Juneja · Chairman and Whole-Time Director
Rajeev Juneja · Vice Chairman and Managing Director
Sheetal Arora · Chief Executive Officer and Whole-Time Director
Ashutosh Dhawan · Chief Financial Officer
Pradeep Chugh · Company Secretary and Compliance Officer
Auto-extracted from the company's RHP using AI, with each fact linked to its source passage (hover any row to see the quote & page). Provided for research only, not investment advice — verify against the official RHP before relying on it.
Mankind Pharma IPO FAQs
What is the lot size of Mankind Pharma IPO?
The minimum lot size of Mankind Pharma IPO is 13 shares. One lot costs ₹14,040 at the cut-off price.
When does Mankind Pharma IPO open and close?
Mankind Pharma IPO opened for subscription on 25 Apr 2023 and closed on 27 Apr 2023.
What is the listing date of Mankind Pharma IPO?
Mankind Pharma IPO listed on 09 May 2023.